1. Thiazolidinediones and the Promise of Insulin Sensitization in Type 2 Diabetes 
Raymond E. Soccio, Eric R. Chen, Mitchell A. Lazar 
Cell Metabolism 
Volume 20, Issue 4, Pages (October 2014)
DOI: /j.cmet
Copyright © 2014 Elsevier Inc. Terms and Conditions

2. Figure 1 The History of TZDs
The graph shows the annual number of TZD-related publications, with boxes indicating key events in the rise and fall of this drug class. For 2014, publications through May were adjusted to a full year.
Cell Metabolism  , DOI: ( /j.cmet )
Copyright © 2014 Elsevier Inc. Terms and Conditions

3. Figure 2 PPARγ Agonist Drugs
TZDs like pioglitazone and rosiglitazone are potent PPARγ agonists (red), but other weaker or partial agonists share the TZD structure with different side chains (blue). There are additional structurally diverse non-TZD PPARγ agoinsts (green and purple), including dual agonists of PPARα and PPARγ (orange). See text for details.
Cell Metabolism  , DOI: ( /j.cmet )
Copyright © 2014 Elsevier Inc. Terms and Conditions

4. Figure 3 Weighing Mortality Risks and Benefits of Pioglitazone
Age-adjusted mortality rates for the entire U.S. population were derived from published government statistics for Potential effects of pioglitazone on mortality from cardiometabolic causes or certain cancers were approximated from published analyses. The mortality from hip fracture is more complex to estimate, as it is not a proximal cause of death but clearly carries mortality risk in the elderly. See text for details.
Cell Metabolism  , DOI: ( /j.cmet )
Copyright © 2014 Elsevier Inc. Terms and Conditions